Memgen
12 Greenway Plaza
Suite 1100
Houston
Texas
77046
United States
Tel: 214-731-3141
Fax: 214-731-3149
Website: http://www.memgenbio.com/
15 articles about Memgen
-
Memgen Announces New Clinical Data on MEM-288 in Advanced/Metastatic NSCLC at ASCO 2023 Annual Meeting
6/6/2023
Memgen, Inc., a clinical-stage biotechnology company today announced updated clinical data from its first-in-human study of MEM-288, an oncolytic viral therapy, in patients with advanced/metastatic refractory non-small cell lung cancer.
-
Memgen Reports Results From Its First-In-Human Clinical Trial of MEM-288 in Solid Tumors Refractory to Checkpoint Inhibitors at SITC 2022
11/30/2022
Memgen, Inc., a biopharmaceutical company developing potentially life-saving cancer immunotherapies, presented the first clinical data for MEM-288, its oncolytic viral therapy, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting in Boston, MA.
-
BioSpace Movers & Shakers, Nov. 19
11/19/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Memgen Appoints Kevin M. Coveney as Chief Financial Officer
11/17/2021
Memgen, Inc., a clinical-stage biotechnology company developing potentially life-saving cancer immunotherapies, announced that Kevin M. Coveney, CPA, has been appointed Chief Financial Officer.
-
Memgen Announces FDA Clearance of IND Application for MEM-288
11/3/2021
Memgen, Inc. announced that the U.S. Food and Drug Administration has accepted its investigational new drug application for MEM-288, the company’s wholly-owned cancer immunotherapy candidate for the treatment of multiple solid tumors.
-
This week, the U.S. Food and Drug Administration accepted Investigational New Drug Applications for multiple companies, clearing the way for clinical development.
-
ImmunoCellular Therapeutics And Memgen Announce Letter Of Intent For Potential Joint Immuno-Oncology Collaboration
3/23/2017
-
Memgen Announces Preclinical Results For Its ISF35 Cancer Immunotherapy With Checkpoint Inhibitors In Metastatic Melanoma
11/18/2015
-
Memgen Announces Upcoming Presentation for ISF35 in Chronic Lymphocytic Leukemia at 2011 Memgen Annual Meeting
12/9/2011
-
Memgen Announces Clinical and Preclinical Results for ISF35 in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma
12/9/2010
-
Memgen's ISF35 Sensitizes Leukemia Cells to Chemotherapy
12/8/2009
-
Memgen's Clinical Trial Results of ISF35 for Chronic Lymphocytic Leukemia Selected for Presentation at American Society of Hematology 2009 Annual Meeting
12/1/2009
-
Memgen Reports Positive Results for ISF35 in High-Risk Chronic Lymphocytic Leukemia
6/4/2009
-
Memgen's ISF35 Clinical Trial Featured at American Society of Clinical Oncology Annual 2009 Meeting
5/26/2009
-
Memgen's Clinical Results on Leukemia Selected for Presentation at 2008 American Society of Hematology Annual Meeting
12/3/2008